The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The pertussis vaccine market, a cornerstone in preventive healthcare, has experienced steady growth, evolving from $5.26 billion in 2023 to a projected $5.5 billion in 2024, boasting a Compound Annual Growth Rate (CAGR) of 4.4%. This upward trajectory is attributed to disease prevalence, robust immunization programs, increased pediatric vaccination, and supportive regulatory approvals. Looking ahead, the forecast anticipates sustained growth, reaching $6.33 billion in 2028 at a CAGR of 3.6%. Let’s delve into the key drivers, major trends, and the impactful role of innovative approvals in shaping the pertussis vaccine landscape.

Surge In Childbirth Rates Fuels Growth Of Pertussis Vaccine Market

• Childbirth Rates Impact
  • Rising childbirth rates contribute to the growth of the pertussis vaccine market.
  • Pertussis vaccine primarily used to protect children from whooping cough and severe diseases.
• Global Statistics
  • CDC reports a rise in US births, from 3.61 million in 2020 to 3.66 million in 2021.
  • Statistics Canada notes a 2% increase in Canadian births, from 360,552 in 2020 to 367,684 in 2021.
• Driving Force
  • The pertussis vaccine market propelled by the increasing number of childbirths globally.

Innovative Approvals Bolster Major Companies In The Pertussis Vaccine Market

• Innovative Drug Approvals
  • Major companies focus on developing and gaining approvals for innovative pertussis vaccines.
  • BOOSTRIX, a Tdap vaccine, approved by the FDA for use during pregnancy to prevent pertussis in newborns.
• Case Study: GSK plc.
  • GSK plc. expands its vaccine portfolio with the acquisition of Affinivax Inc. for $2.1 billion.
  • The acquisition aims to broaden GSK’s scientific footprint, enhance its R&D pipeline, and leverage disruptive vaccine technology.
• Strategic Acquisitions
  • GSK plc.’s acquisition of Affinivax Inc. bolsters its pertussis vaccine offerings and overall vaccine portfolio.

View More On The Pertussis Vaccine Market Report 2023 – https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Innovative Approvals Bolster Major Companies In The Pertussis Vaccine Market

• Innovative Drug Approvals
  • Major companies focus on developing and gaining approvals for innovative pertussis vaccines.
  • BOOSTRIX, a Tdap vaccine, approved by the FDA for use during pregnancy to prevent pertussis in newborns.
• Case Study: GSK plc.
  • GSK plc. expands its vaccine portfolio with the acquisition of Affinivax Inc. for $2.1 billion.
  • The acquisition aims to broaden GSK’s scientific footprint, enhance its R&D pipeline, and leverage disruptive vaccine technology.
• Strategic Acquisitions
  • GSK plc.’s acquisition of Affinivax Inc. bolsters its pertussis vaccine offerings and overall vaccine portfolio.

Market Segmentation and Regional Trends

• Market Segmentation
  • By Product Type: DTaP (Diphtheria, Tetanus, and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria, and Pertussis) Vaccine.
  • By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine.
  • By Application: Children, Adults, Infants.
  • By End-User: Vaccination Centers, Hospitals, Clinics.
• Regional Trends
  • North America: Dominated the pertussis vaccine market in 2023.
  • Continued growth expected, with Asia-Pacific emerging as a significant contributor.

Request A Sample Of The Global Pertussis Vaccine Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13023&type=smp

The Pertussis Vaccine Global Market Report 2023  provides a comprehensive overview on the pertussis vaccine market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Meningococcal Vaccines Global Market Report 2023
Typhoid Vi Polysaccharide Vaccine Global Market Report 2023
Pediatric Vaccine Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model